Cargando…
Augmentation with antidepressants in schizophrenia treatment: benefit or risk
We focused on the application of antidepressants in schizophrenia treatment in this review. Augmentation of antidepressants with antipsychotics is a common clinical practice to treat resistant symptoms in schizophrenia, including depressive symptoms, negative symptoms, comorbid obsessive–compulsive...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4370910/ https://www.ncbi.nlm.nih.gov/pubmed/25834445 http://dx.doi.org/10.2147/NDT.S62266 |
_version_ | 1782362960673374208 |
---|---|
author | Mao, Ye-Meng Zhang, Ming-Dao |
author_facet | Mao, Ye-Meng Zhang, Ming-Dao |
author_sort | Mao, Ye-Meng |
collection | PubMed |
description | We focused on the application of antidepressants in schizophrenia treatment in this review. Augmentation of antidepressants with antipsychotics is a common clinical practice to treat resistant symptoms in schizophrenia, including depressive symptoms, negative symptoms, comorbid obsessive–compulsive symptoms, and other psychotic manifestations. However, recent systematic review of the clinical effects of antidepressants is lacking. In this review, we have selected and summarized current literature on the use of antidepressants in patients with schizophrenia; the patterns of use and effectiveness, as well as risks and drug–drug interactions of this clinical practice are discussed in detail, with particular emphasis on the treatment of depressive symptoms in schizophrenia. |
format | Online Article Text |
id | pubmed-4370910 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-43709102015-04-01 Augmentation with antidepressants in schizophrenia treatment: benefit or risk Mao, Ye-Meng Zhang, Ming-Dao Neuropsychiatr Dis Treat Review We focused on the application of antidepressants in schizophrenia treatment in this review. Augmentation of antidepressants with antipsychotics is a common clinical practice to treat resistant symptoms in schizophrenia, including depressive symptoms, negative symptoms, comorbid obsessive–compulsive symptoms, and other psychotic manifestations. However, recent systematic review of the clinical effects of antidepressants is lacking. In this review, we have selected and summarized current literature on the use of antidepressants in patients with schizophrenia; the patterns of use and effectiveness, as well as risks and drug–drug interactions of this clinical practice are discussed in detail, with particular emphasis on the treatment of depressive symptoms in schizophrenia. Dove Medical Press 2015-03-16 /pmc/articles/PMC4370910/ /pubmed/25834445 http://dx.doi.org/10.2147/NDT.S62266 Text en © 2015 Mao and Zhang. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Review Mao, Ye-Meng Zhang, Ming-Dao Augmentation with antidepressants in schizophrenia treatment: benefit or risk |
title | Augmentation with antidepressants in schizophrenia treatment: benefit or risk |
title_full | Augmentation with antidepressants in schizophrenia treatment: benefit or risk |
title_fullStr | Augmentation with antidepressants in schizophrenia treatment: benefit or risk |
title_full_unstemmed | Augmentation with antidepressants in schizophrenia treatment: benefit or risk |
title_short | Augmentation with antidepressants in schizophrenia treatment: benefit or risk |
title_sort | augmentation with antidepressants in schizophrenia treatment: benefit or risk |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4370910/ https://www.ncbi.nlm.nih.gov/pubmed/25834445 http://dx.doi.org/10.2147/NDT.S62266 |
work_keys_str_mv | AT maoyemeng augmentationwithantidepressantsinschizophreniatreatmentbenefitorrisk AT zhangmingdao augmentationwithantidepressantsinschizophreniatreatmentbenefitorrisk |